ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.

The ELAC2/HPC2 gene at 17p11 is the first candidate gene identified for human prostate cancer (PRCA) based on linkage analysis and positional cloning (S. V. Tavtigian et al. Nat. Genet., 27:172-180, 2001). A truncating mutation was found in one hereditary prostate cancer (HPC) family, whereas two missense variants, Ser217Leu and Ala541Thr, were reported to be associated with increased PRCA risk in the general population. Here, we screened for mutations of the ELAC2/HPC2 gene in 66 Finnish HPC families. Several sequence variants, including a new exonic variant (Glu622Val) were found, but none of the mutations were truncating. We then analyzed the frequency of the three found missense variants in 1365 individuals, including hereditary (n = 107) and unselected (n = 467) PRCA, benign prostatic hyperplasia (n = 223), and population controls (568 healthy male blood donors). Ser217Leu and Ala541Thr variants carried no significantly elevated risk for HPC or PRCA, although the latter variant was associated with benign prostatic hyperplasia. The previously undescribed Glu622Val variant had a 1.0% population prevalence, but a significantly higher frequency in PRCA cases (3.0% odds ratio, 2.94; 95% confidence interval, 1.05-8.23). We conclude that ELAC2/HPC2 truncating mutations are rare in HPC, but that rare variants of the ELAC2/HPC2 require additional study as risk factors for PRCA in the general population.

[1]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[2]  L. Peltonen.  Molecular background of the Finnish disease heritage. , 1997, Annals of medicine.

[3]  F. Wright,et al.  Linkage disequilibrium mapping in isolated populations: the example of Finland revisited. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Syvänen.  Solid-phase minisequencing as a tool to detect DNA polymorphism. , 1998, Methods in molecular biology.

[5]  J. Carpten,et al.  A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Schleutker,et al.  Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. , 2000, Cancer research.

[7]  J. Stanford,et al.  Genetics of prostate cancer: too many loci, too few genes. , 2000, American journal of human genetics.

[8]  T. Rebbeck,et al.  Association of HPC2/ELAC2 genotypes and prostate cancer. , 2000, American journal of human genetics.

[9]  Siavash Ghaffari,et al.  A candidate prostate cancer susceptibility gene at chromosome 17p , 2001, Nature Genetics.

[10]  J. Trachtenberg,et al.  HPC2 variants and screen-detected prostate cancer. , 2001, American journal of human genetics.

[11]  J. Carpten,et al.  Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. , 2001, American journal of human genetics.